Athira Pharma

Athira Pharma, Inc. engages in the development of small molecules to restore neuronal health and stop neurodegeneration. Its product pipeline includes ATH-1017, ATH-1019/20, and ATH-1018. The company was founded by Leen Kawas, John Wright, Lewis Rumpler, and Joseph Harding in March 2011 and is headquartered in Bothell, WA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOTHELL, Wash., March 20, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that study overview and baseline data from ACT-AD, a fully enrolled Phase 2 clinical trial of Athira's lead development candidate, fosgonimeton (ATH-1017) in study participants with mild-to-moderate Alzheimer's disease (AD), were presented in an oral presentation at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Diseases (AD/PD™ 2022) taking place in Barcelona, Spain, and virtually from March 15-20, 2022.

Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease at the 2022 AD/PD™ Congress

BOTHELL, Wash., March 14, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that an overview and update of the fully enrolled ACT-AD Phase 2 clinical trial with Athira's lead development candidate fosgonimeton (ATH-1017) in mild-to-moderate Alzheimer's disease, will be presented at the International Conference on Alzheimer's & Parkinson Diseases™ 2022, AD/PD™ 2022 hybrid​ congress, taking place March 15-20, 2022 virtually and in Barcelona.

Athira Pharma to Present Overview and Update from ACT-AD Phase 2 Trial of Fosgonimeton (ATH-1017) in Mild-to-Moderate Alzheimer's Disease at AD/PD™ 2022 Congress

Active metabolite of fosgonimeton (ATH-1017) enhances the HGF/MET system, resulting in neurotrophic and procognitive effects

Athira Pharma Presents Preclinical Data of Fosgonimeton (ATH-1017) and ATH-1020 at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

Oral presentation on neurotrophic and procognitive properties of the active metabolite of fosgonimeton in preclinical models

Athira Pharma to Present Preclinical Data at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting

BOTHELL, Wash., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Grant Pickering to its Board of Directors. Mr. Pickering is Chief Executive Officer, co-founder and member of the Board of Directors at Vaxcyte, Inc. (NASDAQ: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.

Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors

BOTHELL, Wash., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in SHAPE, a Phase 2 clinical trial of ATH-1017 for the treatment of Parkinson's disease dementia and Dementia with Lewy bodies. ATH-1017 is a small molecule designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor, MET, to impact neurodegeneration and regenerate brain tissue.

Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

Investors need to pay close attention to Athira Pharma (ATHA) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Athira Pharma (ATHA) Stock?

– Balanced baseline characteristics in ACT-AD and LIFT-AD to date – – Topline data from ACT-AD trial targeted for first half of 2022 –

Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer's Disease at CTAD Conference

-Stifel 2021 Virtual Healthcare Conference- - Jefferies 2021 London Healthcare Conference-

Athira Pharma to Present at Upcoming Investor Conferences

BOTHELL, Wash., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced it will host an educational webinar to review event-related potential (ERP) P300 latency as a functional measure of working memory processing speed, and its correlation to cognition. The webinar will be webcast live on Friday, Nov. 5, at 9 a.m. PT / 12 p.m. ET, and will feature presentations by:

Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300

The clinical trial for its Alzheimer's drug is one step closer to completion.

Why Shares of Athira Pharma Are Climbing Today

Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer's Disease

Leen Kawas has formally resigned as CEO of Athira Pharma and is stepping off the board after an investigation found the biotech executive altered images in scientific papers she authored.

Ex-Athira Pharma CEO Leen Kawas resigns and leaves board after image manipulation investigation

BOTHELL, Wash., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that updates and baseline data from two ongoing Phase 2 and Phase 2/3 clinical trials of its lead development candidate ATH-1017, a novel small molecule therapeutic specifically designed to enhance the activity of Hepatocyte Growth Factor (HGF) and its receptor MET, in mild-to-moderate Alzheimer's disease, will be presented as an oral presentation at the upcoming 2021 Clinical Trials on Alzheimer's Disease (CTAD) conference taking place Nov. 9-12, 2021 both virtually and in-person in Boston.

Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer's Disease (CTAD) Conference

Athira Pharma, Inc. (ATHA) closed at $10.13 in the latest trading session, marking a -1.65% move from the prior day.

Athira Pharma, Inc. (ATHA) Dips More Than Broader Markets: What You Should Know

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Athira To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - August 27, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) and reminds investors of the August 24, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Athira stock purchased pursuant...

Athira Shareholder Alert

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Athira Pharma, Inc. ("Athira " or "the Company") (NASDAQ: ATHA) on behalf of shareholders who purchased or otherwise acquired Athira common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with the Company's September 2020 initial public offering

Last Day for Shareholders to Actively Participate in Athira Pharma, Inc. (ATHA) Class Action: Bronstein, Gewirtz & Grossman, LLC

Los Angeles, California--(Newsfile Corp. - August 24, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

San Francisco, California--(Newsfile Corp. - August 24, 2021) -  Hagens Berman urges Athira Pharma, Inc. (NASDAQ: ATHA) investors with significant losses to submit your losses now. A securities class action has been filed and certain investors may have valuable claims. Class Period: Sept. 18, 2020 - June 17, 2021Lead Plaintiff Deadline: Aug. 24, 2021Visit: www.hbsslaw.com/investor-fraud/ATHAContact An Attorney Now: ATHA@hbsslaw.com 844-916-0895Athira Pharma, Inc. (ATHA) Securities Class Action:Since going public...

ATHA DEADLINE TODAY: Hagens Berman Encourages Athira Pharma (ATHA) Investors with Losses to Contact Firm's Attorneys Now, Lead Plaintiff Deadline Today

RANDOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP reminds investors that securities fraud class action lawsuits have been filed against Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira”) on behalf of those who purchased or acquired Athira common stock: a) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Athira's September 2020 initial public offering (“IPO”); and/or b) betw

Kessler Topaz Meltzer & Checker, LLP: Final Deadline Reminder for Athira Pharma, Inc. Investors – ATHA

CorMedix

View

NEW YORK, NY / ACCESSWIRE / August 23, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for ATHA, CRMD and VIEW: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Los Angeles, California--(Newsfile Corp. - August 23, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Athira Pharma, Inc. ("Athira" or "the Company") (NASDAQ: ATHA) for violations of the federal securities laws.Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO"), or between September 18, 2020 and June 17, 2021, both dates...

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Athira Pharma, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

BOTHELL, Wash., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Chief Medical Officer, Hans Moebius, will present on the application of clinically established Evoked-Response Potentials (ERPs) by using ERP P300 in Alzheimer's drug development, and the utility of ERP P300 in Athira's Phase 1 clinical trials, at the Annual Biomarkers for Alzheimer's Disease Summit taking place virtually August 24-26, 2021.

Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer's Disease Summit

New York, New York--(Newsfile Corp. - August 23, 2021) - WHY: New York, N.Y., August 22, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Athira Pharma, Inc. (NASDAQ: ATHA): (a) pursuant and/or traceable to the Company's initial public offering conducted in September 2020 (the "IPO" or "Offering"); and/or (b) between September 18, 2020 and June 17, 2021, both dates inclusive (the "Class Period"), of the important August...

FINAL DEADLINE TUESDAY: ROSEN, A LEADING LAW FIRM, Encourages Athira Pharma, Inc. Investors to Secure Counsel Before Important August 24 Deadline in Securities Class Action - ATHA

LOS ANGELES--(BUSINESS WIRE)---- $ATHA #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Athira Pharma, Inc. (ATHA)

News for Athira Pharma Stock (ATHA)